Travere Therapeutics Appoints Jula Inrig, M.D., as Chief Medical Officer
04. Januar 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Jula Inrig, M.D., as chief medical officer, effective immediately. Dr. Inrig...
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
15. September 2021 16:05 ET
|
Travere Therapeutics, Inc.
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory...
Retrophin Provides Corporate Update and 2020 Outlook
13. Januar 2020 06:59 ET
|
Retrophin, Inc.
SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the...